

Sarcopenia - Pipeline Review, H2 2020

<https://marketpublishers.com/r/SDB104C729BEN.html>

Date: July 2020

Pages: 98

Price: US\$ 2,000.00 (Single User License)

ID: SDB104C729BEN

Abstracts

Sarcopenia - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sarcopenia - Pipeline Review, H2 2020, provides an overview of the Sarcopenia (Musculoskeletal Disorders) pipeline landscape.

Sarcopenia is an aging-associated condition which is characterized by loss of muscle mass, strength and function. Symptoms include weakness, loss of endurance and poor balance. Causes of sarcopenia include a reduction in the nerve cells, low hormone levels and decline in body's ability to convert protein to energy. Treatment includes hormone replacement therapy (HRT), exercise and dietary supplements.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sarcopenia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Sarcopenia (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sarcopenia (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sarcopenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 2, 13, 4 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and

2 molecules, respectively.

Sarcopenia (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Sarcopenia (Musculoskeletal Disorders).

The pipeline guide reviews pipeline therapeutics for Sarcopenia (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Sarcopenia (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Sarcopenia (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline

projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Sarcopenia (Musculoskeletal Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Sarcopenia (Musculoskeletal Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Sarcopenia (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Sarcopenia - Overview
- Sarcopenia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Sarcopenia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Sarcopenia - Companies Involved in Therapeutics Development
- AAVogen Inc
- Armgo Pharma Inc
- Bioleaders Corp
- Biophytis SA
- Dystrogen Therapeutics SA
- Elevian Inc
- Faraday Pharmaceuticals Inc
- Gerologix Inc
- Helixmith Co Ltd
- Keren Therapeutics
- MYOS RENS Technology Inc
- Neurotune AG
- Oncocross Co Ltd
- OPKO Health Inc
- PhaseBio Pharmaceuticals Inc
- Rejuvenate Biomed NV
- Ridgeline Therapeutics LLC
- ST Pharm Co Ltd
- Teijin Pharma Ltd
- Vibe Pharmaceuticals LLC
- Sarcopenia - Drug Profiles
- ARM-210 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
AVGN-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIO-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sarcopenia - Dormant Projects
Sarcopenia - Discontinued Products
Sarcopenia - Product Development Milestones
Featured News & Press Releases
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Sarcopenia, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Sarcopenia - Pipeline by AAVogen Inc, H2 2020
Sarcopenia - Pipeline by Armgo Pharma Inc, H2 2020
Sarcopenia - Pipeline by Bioleaders Corp, H2 2020
Sarcopenia - Pipeline by Biophytis SA, H2 2020
Sarcopenia - Pipeline by Dystrogen Therapeutics SA, H2 2020
Sarcopenia - Pipeline by Elevian Inc, H2 2020
Sarcopenia - Pipeline by Faraday Pharmaceuticals Inc, H2 2020
Sarcopenia - Pipeline by Gerologix Inc, H2 2020
Sarcopenia - Pipeline by Helixmith Co Ltd, H2 2020
Sarcopenia - Pipeline by Keren Therapeutics, H2 2020
Sarcopenia - Pipeline by MYOS RENS Technology Inc, H2 2020
Sarcopenia - Pipeline by Neurotune AG, H2 2020
Sarcopenia - Pipeline by Oncocross Co Ltd, H2 2020
Sarcopenia - Pipeline by OPKO Health Inc, H2 2020
Sarcopenia - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2020
Sarcopenia - Pipeline by Rejuvenate Biomed NV, H2 2020
Sarcopenia - Pipeline by Ridgeline Therapeutics LLC, H2 2020
Sarcopenia - Pipeline by ST Pharm Co Ltd, H2 2020
Sarcopenia - Pipeline by Teijin Pharma Ltd, H2 2020
Sarcopenia - Pipeline by Vibe Pharmaceuticals LLC, H2 2020
Sarcopenia - Dormant Projects, H2 2020
Sarcopenia - Dormant Projects, H2 2020 (Contd..1), H2 2020
Sarcopenia - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Sarcopenia, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

AAVogen Inc
Armgo Pharma Inc
Bioleaders Corp
Biophytis SA
Dystrogen Therapeutics SA
Elevian Inc
Faraday Pharmaceuticals Inc
Gerologix Inc
Helixmith Co Ltd
Keren Therapeutics
MYOS RENS Technology Inc
Neurotune AG
Oncocross Co Ltd
OPKO Health Inc
PhaseBio Pharmaceuticals Inc
Rejuvenate Biomed NV
Ridgeline Therapeutics LLC
ST Pharm Co Ltd
Teijin Pharma Ltd
Vibe Pharmaceuticals LLC

I would like to order

Product name: Sarcopenia - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/SDB104C729BEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SDB104C729BEN.html>